Bivalirudin Injection 0.25g (250 mg) is an intravenous, direct thrombin inhibitor anticoagulant. On platforms like Wikipedia or Wikidoc, it is classified as a synthetic 20-amino acid peptide that acts as a potent and reversible "blood thinner".
Core Medical Information
- Mechanism of Action: It binds directly and reversibly to both the active catalytic site and the exosite-1 of thrombin. This prevents thrombin from converting fibrinogen into fibrin, effectively blocking the final step of blood clot formation.
- Primary Clinical Indications:
- Pharmacokinetics: Administered strictly via intravenous (IV) bolus followed by continuous infusion. It has a very short elimination half-life of approximately 25 minutes in patients with normal renal function, primarily cleared by internal proteolysis (80%) and renal excretion (20%).
- Main Adverse Effects: The most critical risk is bleeding. However, clinical studies (such as REPLACE-2 and HORIZONS-AMI) have shown that bivalirudin carries a lower risk of severe bleeding complications compared to traditional heparin-based regimens.